Analytical Data
-
Gene name
CDK9
- Application
-
Alternative Names
CDK9；CDC2L4；TAK；Cyclin-dependent kinase 9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P50750
-
Expression Region
1-372aa
-
AA Sequence
MAKQYDSVEC PFCDEVSKYE KLAKIGQGTF GEVFKARHRK TGQKVALKKV LMENEKEGFP ITALREIKIL QLLKHENVVN LIEICRTKAS PYNRCKGSIY LVFDFCEHDL AGLLSNVLVK FTLSEIKRVM QMLLNGLYYI HRNKILHRDM KAANVLITRD GVLKLADFGL ARAFSLAKNS QPNRYTNRVV TLWYRPPELL LGERDYGPPI DLWGAGCIMA EMWTRSPIMQ GNTEQHQLAL ISQLCGSITP EVWPNVDNYE LYEKLELVKG QKRKVKDRLK AYVRDPYALD LIDKLLVLDP AQRIDSDDAL NHDFFWSDPM PSDLKGMLST HLTSMFEYLA PPRRKGSQIT QQSTNQSRNP ATTNQTEFER VF
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK9, or Cyclin-Dependent Kinase 9, is a pivotal enzyme that plays a critical role in the regulation of transcription and cell cycle progression. It is a key member of the CDK family, primarily associated with RNA polymerase II phosphorylation, which is essential for the transcriptional elongation process. Dysregulation of CDK9 has been implicated in various pathological conditions, including cancer, where aberrant expression or activity contributes to uncontrolled cellular proliferation. Research into CDK9 has gained momentum due to its potential as a therapeutic target; various small molecule inhibitors are being explored for their ability to selectively inhibit CDK9 activity. Recombination and expression of CDK9 in heterologous systems have been crucial for studying its biochemical properties and interactions with regulatory proteins, enabling a deeper understanding of its role in transcriptional control. Investigating the structural and functional characteristics of CDK9 through recombinant protein techniques enhances our knowledge of its enzymatic mechanisms and aids in the development of novel inhibitors that could serve as effective cancer treatments. As a result, the study of CDK9 recombinant proteins continues to represent a significant area of research with promising implications for targeted therapies in oncology and other related diseases.
